Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;59(5):670-677.
doi: 10.1007/s11262-023-02013-y. Epub 2023 Jun 16.

Preparation of monoclonal antibodies against Epstein-Barr virus glycoprotein 350

Jiao Zheng  1 , Xuan Zeng  2 , Linxiu Zeng  1 , Ye Xu  3 , Zhihong Zhong  1 , Yi Wu  4 , Yilan Qiu  5 , Rushi Liu  6
Affiliations

Preparation of monoclonal antibodies against Epstein-Barr virus glycoprotein 350

Jiao Zheng et al. Virus Genes. 2023 Oct.

Abstract

Epstein-Barr virus (EBV) is the first identified human oncogenic herpesvirus infecting over 90% of the adults worldwide. However, the safe and effective prophylactic vaccine has not been licensed. The major glycoprotein 350 (gp350) on the EBV envelope is the main target for neutralizing antibodies, and gp350 (aa15-320) was used for the development of monoclonal antibodies in present study. The purified recombinant gp35015-320aa with an estimated molecular weight of 50 kDa was used to immunize six-week-old BALB/c mice, and the hybridoma cell lines that stably secreted monoclonal antibodies (mAbs) were obtained. The ability of developed mAbs for capturing and neutralizing EBV was evaluated, and mAb 4E1 presented better performance to block the infection of EBV in cell line Hone-1. The mAb 4E1 recognized the epitope. Its sequence of variable region genes (VH and VL) presented a unique identity which hadn't been reported. The developed mAbs might benefit the antiviral therapy and immunologic diagnosis for EBV infection.

Keywords: Epitope; Epstein-Barr virus (EBV); Glycoprotein 350; Infection-blocking; Monoclonal antibody.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Shannon-Lowe C, Rickinson A (2019) The global landscape of EBV-associated tumors. Front Oncol 9:713. https://doi.org/10.3389/fonc.2019.00713 - DOI - PubMed - PMC
    1. Wong Y, Meehan MT, Burrows SR, Doolan DL, Miles JJ (2022) Estimating the global burden of Epstein-Barr virus-related cancers. J Cancer Res Clin Oncol 148(1):31–46. https://doi.org/10.1007/s00432-021-03824-y - DOI - PubMed
    1. Cao Y, Xie L, Shi F, Tang M, Li Y, Hu J, Zhao L, Zhao L, Yu X, Luo X, Liao W, Bode AM (2021) Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduct Target Ther 6(1):15. https://doi.org/10.1038/s41392-020-00376-4 - DOI - PubMed - PMC
    1. Klein G (2015) Tumor associations of EBV–historical perspectives. Curr Top Microbiol Immunol 390(Pt 1):17–22. https://doi.org/10.1007/978-3-319-22822-8_2 - DOI - PubMed
    1. Young LS (2020) A novel Epstein-Barr virus subtype associated with nasopharyngeal carcinoma found in South China. Cancer Commun (Lond) 40(1):60–62. https://doi.org/10.1002/cac2.12006 - DOI - PubMed

LinkOut - more resources